Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever
CLINICAL TRANSPLANTATION, cilt.32, sa.8, 2018 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 32 Sayı: 8
- Basım Tarihi: 2018
- Doi Numarası: 10.1111/ctr.13345
- Dergi Adı: CLINICAL TRANSPLANTATION
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır
Özet
Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.